Navigation Links
OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial
Date:5/30/2009

se technology, licensed from Isis Pharmaceuticals (NASDAQ: ISIS), to effectively target and inhibit production of specific proteins in tumor cells. OncoGenex and Isis partnered in the successful discovery of OGX-011, OGX-427 and OGX-225 and with respect to OGX-011, in its initial development. In 2008, OncoGenex and Isis amended their OGX-011 agreement to provide OncoGenex with sole rights to OGX-011 and sole responsibility for development and related costs and partnering decisions, subject to financial obligations to Isis. OncoGenex is also solely responsible for development and related costs and partnering decisions regarding OGX-427 and OGX-225. Key intellectual property related to OGX-011, OGX-427 and OGX-225 were discovered by the University of British Columbia and the Vancouver Prostate Centre, and were exclusively licensed to OncoGenex.

More information about OncoGenex is available at www.oncogenex.com.

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements concerning the potential survival benefit of OGX-011, anticipated clinical development activities, timing of these activities, the ability of future trials to demonstrate clinical benefit and the potential for regulatory approvals. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements.

The potential risks and uncertainties associated with forward-looking statements include, among
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. OncoGenex Pharmaceuticals to Webcast ASCO Reception on May 30, 2009
2. OncoGenex Pharmaceuticals Announces Release of Two ASCO Abstracts: Impact of OGX-011 on Survival in Randomized Phase 2 Trial and Phase 1 Safety Data for OGX-427
3. OncoGenex Pharmaceuticals Clinical Programs to be Featured in Oral Presentations at the American Society of Clinical Oncology Annual Meeting
4. OncoGenex Reports First Quarter Financial Results
5. OncoGenex Pharmaceuticals to Release First Quarter Financial Results
6. OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer
7. OncoGenex Pharmaceuticals Named Life Sciences Company of the Year by LifeSciences British Columbia
8. OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009
9. OncoGenex Pharmaceuticals to Webcast Financial Results for Fourth Quarter and Fiscal Year 2008 and Provide Outlook for 2009
10. OncoGenex Provides Update on Two-Year Survival Data from Ongoing Phase 1/2 Clinical Trial of OGX-011 in Non-Small Cell Lung Cancer
11. OncoGenex To Present At The RBC Capital Markets 2008 Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... Vt. (PRWEB) August 28, 2014 ... testing around the world is available from Strategic ... diagnostics companies. “ Industrial Microbiology Market Review, Fourth ... Industrial Market ” (IMMR—4) tracks and compares microbiology ... in North America, Europe and Asia, and forecasts ...
(Date:8/28/2014)... PrimeSource Building Products, Inc., a leading ... to support their communication needs with the ... conferencing platform GlobalMeet powered by SoundConnect. The solution ... SoundConnect delivers award winning “results driven” business class ... be utilizing GlobalMeet powered by SoundConnect ...
(Date:8/28/2014)... Whitehouse Laboratories is excited to announce ... PTI Inspection Systems that will enable it ... art leak testing method development and validation programs using ... As part of this agreement, Whitehouse Labs has taken ... Instrument developed and manufactured by PTI. The HVLD ...
(Date:8/27/2014)... (PRWEB) August 27, 2014 Green & ... in Series B funding and secured Otter Capital as ... capital will accelerate commercialization of GGI’s Agriplier™ technology, building ... types. , “Since our first meeting, we have ... the biological product space,” said Alan Sobba, President and ...
Breaking Biology Technology:2 Billion Industrial Microbiology Tests Conducted for Product Quality and Safety Worldwide 22 Billion Industrial Microbiology Tests Conducted for Product Quality and Safety Worldwide 3PrimeSource Chooses SoundConnect as Collaboration Provider 2Whitehouse Labs Renews Partnership with PTI Inspection Systems 2Whitehouse Labs Renews Partnership with PTI Inspection Systems 3Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 2Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 3
... Stem Cell Institute,(RSCI) today announced two additions to ... cell research proficiency in the process.,Don Margolis, RSCI ... two,things in common: pioneering stem cell research and ... incurable. Today we add two,Massachusetts researchers, David Matzilevich, ...
... - Company Appoints Charles Rowland to Chief Financial ... ViroPharma Incorporated,(Nasdaq: VPHM ) today announced that ... strengthened its leadership in human resources,clinical development and ... vice president and chief financial officer; Thomas Macnamara ...
... Force ... ANX-514, - Company to Present Updated Corporate Outlook at ... Pharmaceuticals,Inc. (Amex: ANX ) announced today that it has ... towards the,Company,s near term goals. ADVENTRX will focus its resources ...
Cached Biology Technology:RSCI Announces Two Additions to Its Science Advisory Board, Calling for More Stem Cell Research on Diabetes 2ViroPharma Enhances Leadership to Support Global Growth and Expanding Business 2ViroPharma Enhances Leadership to Support Global Growth and Expanding Business 3ViroPharma Enhances Leadership to Support Global Growth and Expanding Business 4ViroPharma Enhances Leadership to Support Global Growth and Expanding Business 5ADVENTRX Announces Restructuring and Cost Reduction Initiatives 2ADVENTRX Announces Restructuring and Cost Reduction Initiatives 3ADVENTRX Announces Restructuring and Cost Reduction Initiatives 4ADVENTRX Announces Restructuring and Cost Reduction Initiatives 5ADVENTRX Announces Restructuring and Cost Reduction Initiatives 6
(Date:8/28/2014)... A new study reports that an expansion of marine ... perform key ecological functions. According to investigators from ... at protecting fish have focused on saving the largest ... species that provide key and difficult-to-replace ecological functions. ... are performed by fish species that also are food ...
(Date:8/28/2014)... Access to Research Careers) Program has announced the travel ... from October 18 22, 2014 in San Diego, ... entry of students, post doctorates and scientists from underrepresented ... and to encourage the participation of young scientists at ... MARC conferred 16 awards totaling $29,600., The FASEB MARC ...
(Date:8/28/2014)... FASEB MARC (Maximizing Access to Research Careers) Program ... Genetics Society of America,s 27th Annual Mouse Molecular ... 2014 in Pacific Grove, California. These awards ... post doctorates and scientists from underrepresented groups into ... to encourage the participation of young scientists at ...
Breaking Biology News(10 mins):Study finds marine protected areas inadequate for protecting fish and ocean ecology 2
... fungi, often found in composts that self-ignite without flame or ... of Myceliophthora thermophila and Thielavia terrestris ... The findings, published in Nature Biotechnology , may ... chemicals and other industrial materials. "Organisms that thrive ...
... release is available in German . They ... model of evolutionary success: viruses. Viruses are extremely adaptable but they ... into suitable host cells. In the case of some viruses, the ... has been known for almost 50 years. We know, for instance, ...
... Spanish . , The cayenne tick has ... in horses in a 2009 Texas outbreak, according to U.S. ... been considered free from the disease since 1978, but sporadic ... Kleberg County, Texas, a mare was presented for veterinary care ...
Cached Biology News:From compost to sustainable fuels: Heat-loving fungi sequenced 2Manipulated gatekeeper: How viruses find their way into the cell nucleus 2Tick responsible for equine piroplasmosis outbreak identified 2
The BD CBA Human Apoptosis Kit can be used to quantitatively measure,cleaved PARP, Bcl-2, and active Caspase-3 protein levels in a single sample. The,Kit performance has been optimized for analysis o...
... Activation of ICE-family proteases/caspases initiates apoptosis in ... Apoptosis Detection Kit provides a simple and ... by flow cytometry in intact cells. ... two aspartate residues linked to rhodamine 110 ...
The PROTEAN II slab gel casting stand is a component of the PROTEAN II XL and xi casting apparatus. It is supplied with gaskets....
... direct antibiotic-based selection system for recombinant identification. ... eliminating the need for costly color screening. ... to 100% accuracy in recombinant selection. pLivSelect ... colony picking. This cloning kit can be ...
Biology Products: